StreetInsider.com News Articles

Form 4 CHAMPIONS ONCOLOGY, INC. For: Oct 15 Filed by: ACKERMAN JOEL

Fri, 16 Oct 2026 12:45:00 -0400

si-local-file:///var/storage/secattach/20261016/27197276.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Oct 14

Fri, 16 Oct 2026 12:15:00 -0400

si-local-file:///var/storage/secattach/20261016/27197178.html

Form 10-Q CHAMPIONS ONCOLOGY, INC. For: Jul 31

Fri, 11 Sep 2026 14:51:00 -0400

si-local-file:///var/storage/secattach/20260911/27052546.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Sep 10

Thu, 10 Sep 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260910/27049143.html

Champions Oncology (CSBR) Tops Q1 EPS by 6c

Thu, 10 Sep 2026 16:06:16 -0400

Champions Oncology (NASDAQ: CSBR) reported Q1 EPS of $0.05, $0.06 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $15.05 million.

For earnings history and earnings-related data on Champions Oncology (CSBR) click here.

Champions Oncology Reports Revenue of $15.2 Million

Thu, 10 Sep 2026 16:00:00 -0400

Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000

HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026.

First Quarter and Recent Highlights:

Revenue of $15.2 million, an increase of 8.8% year over year
Oncology services margin of 51%, compared with 43% in the prior-year period
Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period
Continued investment in the Company's commercial organization, data platform and strategic

Champions Oncology Reports Revenue of $15.2 Million

Thu, 10 Sep 2026 16:00:00 -0400

Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000

First Quarter and Recent Highlights:

Revenue of $15.2 million, an increase of 8.8% year over year
Oncology services margin of 51%, compared with 43% in the prior-year period
Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period
Continued investment in the Company's commercial organization, data platform and strategic

Form DEFA14A CHAMPIONS ONCOLOGY, INC.

Fri, 28 Aug 2026 15:37:00 -0400

si-local-file:///var/storage/secattach/20260828/26997511.html

Form DEFA14A CHAMPIONS ONCOLOGY, INC.

Fri, 28 Aug 2026 15:37:00 -0400

si-local-file:///var/storage/secattach/20260828/26997511.html

Form DEF 14A CHAMPIONS ONCOLOGY, INC. For: Aug 27

Fri, 28 Aug 2026 15:36:00 -0400

si-local-file:///var/storage/secattach/20260828/26997507.html

Form DEF 14A CHAMPIONS ONCOLOGY, INC. For: Aug 27

Fri, 28 Aug 2026 15:36:00 -0400

si-local-file:///var/storage/secattach/20260828/26997507.html

Form 10-K CHAMPIONS ONCOLOGY, INC. For: Apr 30

Mon, 27 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260727/26820286.html

Form 10-K CHAMPIONS ONCOLOGY, INC. For: Apr 30

Mon, 27 Jul 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260727/26820286.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Jul 27

Mon, 27 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260727/26820141.html

Form 8-K CHAMPIONS ONCOLOGY, INC. For: Jul 27

Mon, 27 Jul 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260727/26820141.html

Champions Oncology (CSBR) Tops Q4 EPS by 6c

Mon, 27 Jul 2026 16:10:22 -0400

Champions Oncology (NASDAQ: CSBR) reported Q4 EPS of $0.01, $0.06 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $12.89 million.

For earnings history and earnings-related data on Champions Oncology (CSBR) click here.

Champions Oncology Reports Record Annual Revenue of $59 Million

Mon, 27 Jul 2026 16:00:00 -0400

Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA

HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026.

Fourth Quarter and Other Financial Highlights:

Record annual revenue of $59.4 million
Fourth quarter revenue of $13.8 million
Fourth quarter oncology services margin of 51%
Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year
Adjusted EBITDA income all four quarters in FY 2026
Continued

Champions Oncology Reports Record Annual Revenue of $59 Million

Mon, 27 Jul 2026 16:00:00 -0400

Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA

Fourth Quarter and Other Financial Highlights:

Record annual revenue of $59.4 million
Fourth quarter revenue of $13.8 million
Fourth quarter oncology services margin of 51%
Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year
Adjusted EBITDA income all four quarters in FY 2026
Continued

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026

Mon, 20 Jul 2026 16:30:00 -0400

HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. ET (1:30 P.M. PT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 347142. A replay of the call will

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026

Mon, 20 Jul 2026 16:30:00 -0400

Champions Oncology to present research findings at AACR 2026 conference

Thu, 09 Apr 2026 13:40:12 -0400

Champions Oncology, Inc. (NASDAQ: CSBR) announced it will present eight poster presentations at the American Association for Cancer Research Annual Meeting from April 17-22, 2026, in San Diego, California.

The presentations will cover research on KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates, and CAR-T therapies. The studies utilize patient-derived models combined with molecular, functional, and phenotypic data.

The company stated the research demonstrates approaches for predicting therapeutic response and resistance in oncology drug development. The data aims to show how preclinical models can help identify biomarkers and inform development decisions.

"At AACR 2026, we are presenting data that directly address one of

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Thu, 09 Apr 2026 13:40:00 -0400

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions

HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California.

The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals,